Abstract: The present invention relates to a process of preparing a compound of the following formula III: wherein R1-R4 are as defined herein. The present invention also relates to the preparation of intermediates used to prepare the compound of formula III.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
November 20, 2012
Assignee:
GlaxoSmithKline LLC
Inventors:
Nicole Marie Deschamps, Michael Tolar Martin, Michael John Monteith, Xiaoming Zhou
Abstract: Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.
Abstract: New processes for improving the manufacture of clavams e.g. clavulanic acid. Novel DNA sequences and new microorganisms capable of producing increased amounts of clavulanic acid are also disclosed.
Type:
Grant
Filed:
April 13, 2004
Date of Patent:
November 24, 2009
Assignees:
Glaxo Group Limited, The Governors of the University of Alberta
Inventors:
Barry Barton, Alison Michelle Griffin, Susan Jensen, Annie Wong
Abstract: This invention relates to a method for determining the activity of Lp-PLA2 in a plurality of samples from animals. The invention also relates to a kit for determining Lp-PLA2 activity in a plurality of samples.
Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.
Type:
Grant
Filed:
October 18, 2006
Date of Patent:
March 17, 2009
Assignee:
SmithKline Beecham Corporation
Inventors:
Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Inventors:
Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
Type:
Grant
Filed:
April 18, 2005
Date of Patent:
January 1, 2008
Assignee:
SmithKline Beecham Corporation
Inventors:
Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
Abstract: The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory arthropathy or inflammatory disorder, and the use of OSM in screening for such antagonists.
Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.
Type:
Grant
Filed:
August 20, 2002
Date of Patent:
June 12, 2007
Assignee:
SmithKline Beecham Corporation
Inventors:
Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
Abstract: This invention relates in general to certain substituted substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamides of formula I as defined herein which are protease inhibitors.
Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human ?v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.
Type:
Grant
Filed:
May 9, 2002
Date of Patent:
August 8, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Kyung O Johanson, Zdenka Ludmila Jonak, Alexander Taylor, Stephen H Trulli
Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
Type:
Grant
Filed:
August 3, 2001
Date of Patent:
May 16, 2006
Assignee:
SmithKline Beecham plc
Inventors:
Colin Houston MacPhee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
Abstract: A compound of Formula (I): wherein: R1 is C1-6 alkyl, benzyl, or (CH2)n—C(O)NH2; wherein the benzyl may be unsubstituted or substituted by one or two C1-6 alkyl, halogen, C1-6 alkoxy, or methylenedioxy groups; R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, C1-3 alkyl, C1-3 alkoxy, or methylenedioxy groups; X1 and X2 are independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy, nitro, CF3, or CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 29, 2005
Date of Patent:
March 28, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Dashyant Dhanak, Steven D. Knight, Jian Jin, Ralph A. Rivero, Anthony Sapienza
Abstract: DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin ?-lactams and such enzymes are expressed by hosts into which the recombinant vectors are transformed. The DNA and the enzymes encoded thereby have utility in the preparation of penicillins and cephalosporins, both known and novel, possessing pharmacological, especially antimicrobial, activity.
Type:
Grant
Filed:
March 31, 2003
Date of Patent:
November 15, 2005
Assignee:
Beecham Group plc
Inventors:
Martin Karl Russel Burnham, Ian David Normansell, John Edward Hodgson
Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Inventors:
Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.The questions raised in reexamination request, 09/006,966 filed Mar. 12, 2004 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.
Type:
Grant
Filed:
May 27, 2005
Date of Patent:
February 19, 2008
Assignee:
SmithKline Beecham Corporation
Inventors:
Paula Shadle, John C. Erickson, Robert G. Scott, Thomas M. Smith
Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
November 17, 2009
Assignees:
SmithKline Beecham Corporation, University of Texas Southwestern Medical Center at Dallas
Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecular proteins.
Type:
Grant
Filed:
May 18, 2007
Date of Patent:
August 24, 2010
Assignee:
Glaxosmithkline LLC
Inventors:
Paula Shadle, John C. Erickson, Robert G. Scott, Thomas M. Smith
Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.
Type:
Grant
Filed:
March 13, 2009
Date of Patent:
August 31, 2010
Assignee:
GlaxoSmithKline LLC
Inventors:
Paul J. Shandle, John C. Erickson, Robert G. Scott, Thomas M. Smith